David Spencer, MD, director of the Comprehensive Epilepsy Center and professor of neurology at Oregon Health and Science University, talks about the first-in-human trial of interneuron cell therapy for treatment of focal epilepsy and explains the next steps.
The first phase of a first-in-human trial of NRTX-1001, an intraneuron cell therapy treatment for epilepsy, focused on safety, and next will come a randomized, controlled trial to assess efficacy, according to David Spencer, MD, director of the Comprehensive Epilepsy Center and professor of neurology at Oregon Health and Science University.
Transcript
How long is the clinical trial for interneuron cell therapy for treatment of focal epilepsy, and what are the next steps if it proves to be successful?
The cell therapy approach for treating epilepsy that we're exploring is a major commitment to the participants who've taken a big step to join into this study. It's a long-term approach. From the perspective of a person entering into the trial, the main part of the study lasts 2 years, but there's an extension study that continues beyond that for up to 15 years, where we'll continue to follow people and track their outcomes.
From the perspective of the overall study, It has 2 phases. The first phase we’re especially focusing on the safety of doing the cell implants, and so we're going at a cautious pace. After the first implant was completed last June, there was a waiting period, there was a lot of safety assessments and a committee met to ensure that the outcome looks good in that person before we moved on to doing an implant in the second person, which was in last fall of 2022. We're anticipating 5 participants receiving the cell implants, another pause in assessments, a second 5 potentially at a higher dose of cells.
And then at that point in the trial, we'll shift into a hybrid approach continuing to look at safety, but also looking more closely at efficacy. The second phase will be a small, randomized controlled trial, so some people will get cell therapy initially, others will get delayed therapy, and we'll try to look very carefully at the responses that are very specific to cell implants.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
AUA Session Highlights the General Urologist’s Role in Gender-Affirming Care
May 7th 2024During her session, Polina Reyblat, MD, Kaiser Permanente Los Angeles Medical Center, highlighted best practices urologists should incorporate to make transgender and gender-diverse patients comfortable during physical exams and avoid retraumatization.
Read More